Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.

about

Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.

Item

http://www.wikidata.org/entity/Q49518769

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Real-world predictors of 12-mo ...... he ACTION observational study.

@en

Real-world predictors of 12-mo ...... he ACTION observational study.

@nl

type

Item

label

Real-world predictors of 12-mo ...... he ACTION observational study.

@en

Real-world predictors of 12-mo ...... he ACTION observational study.

@nl

prefLabel

Real-world predictors of 12-mo ...... he ACTION observational study.

@en

Real-world predictors of 12-mo ...... he ACTION observational study.

@nl

P1476

Real-world predictors of 12-mo ...... he ACTION observational study.

@en

P2093

Alain Cantagrel

http://www.w3.org/2001/XMLSchema#string

Christiane Rauch

http://www.w3.org/2001/XMLSchema#string

Hanns-Martin Lorenz

http://www.w3.org/2001/XMLSchema#string

Hubert G Nüßlein

http://www.w3.org/2001/XMLSchema#string

Manuela Le Bars

http://www.w3.org/2001/XMLSchema#string

Melanie Chartier

http://www.w3.org/2001/XMLSchema#string

Rieke Alten

http://www.w3.org/2001/XMLSchema#string

Xavier Mariette

http://www.w3.org/2001/XMLSchema#string

Yedid Elbez

http://www.w3.org/2001/XMLSchema#string

P2860

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases

Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.

CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients.

The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis.

P304

e000538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/RMDOPEN-2017-000538

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mauro Galeazzi

P577

2017-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29435360

http://www.w3.org/2001/XMLSchema#string

P932

5761291

http://www.w3.org/2001/XMLSchema#string